RESEARCH ARTICLE

Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool

Ann Levin¹, Safina Yuma², Edwin Swai³, Winthrop Morgan¹, Cindy L. Gauvreau⁴, Nathalie Broutet⁵, Karene Hoi Ting Yeung⁶ and Raymond Hutubessy⁶*

Abstract
Background: The World Health Organization (WHO) has developed a costing tool, the Cervical Cancer Prevention and Control Costing (C4P) tool, to estimate the comprehensive cost of cervical cancer primary, secondary and tertiary prevention in low- and middle-income countries. The tool was piloted in the United Republic of Tanzania, a country with a high incidence of cervical cancer with 62.5 cases per 100,000 women in 2020. This paper presents the costing tool methods as well as the results from the pilot in Tanzania.

Methods: The C4P tool estimates the incremental costs of cervical cancer prevention and control programmes. It estimates the financial (monetary costs to the government) and economic costs (opportunity costs). For the pilot, the study team collected data on costs and programme assumptions for human papillomavirus (HPV) vaccination of 14-year-old girls and scaling up of cervical cancer screening (visual inspection with acetic acid and HPV-DNA testing) and treatment for women for 2020–2024. Assumptions were made on how vaccination coverage would increase over the 5 years as well as developing additional screening and treatment capacity through health personnel training and infrastructure strengthening.

Results: The total financial and economic costs of the comprehensive programme during 2020–2024 are projected to be US$68 million and US$124 million, respectively. The financial and economic costs of a fully immunized girl with HPV vaccine are estimated to be US$6.68 and US$17.31, respectively, while the costs per woman screened for cervical cancer are, on average, US$4.02 and US$5.83, respectively; US$6.44 and US$9.37 for pre-cancer treatment, respectively; and US$101 and US$107 for diagnosis of invasive cancer, respectively. The cost of treating and managing invasive cancer range from US$7.05 and US$7.83 for outpatient palliative care to US$800.21 and US$893.80 for radiotherapy, respectively.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: The C4P costing tool can assist national cervical cancer programmes to estimate monetary resources needed as well as opportunity costs of reducing national cervical cancer incidence through primary, secondary and tertiary prevention.

Keywords: Costing, Cervical cancer, Human papillomavirus (HPV), Vaccines, Immunization programmes, Screening, Treatment, United Republic of Tanzania

Background
Cervical cancer is the fourth most common cancer among women globally with 604,127 annual new cases and 341,831 deaths in 2020 [1]. The World Health Organization has launched a global strategy to accelerate countries to eliminate cervical cancer as a public health problem by the end of this century [2]. This strategy proposes to reduce cervical cancer incidence and mortality through reaching by 2030 and maintaining along the years the following targets: 90% coverage for the full course of human papillomavirus (HPV) vaccination for girls by 15 years of age, 70% screening coverage of eligible women twice in their lifetime by 35 and 45 years of age with a high-performance test and provision of treatment and management care for 90% of women with pre-cancer and invasive cancer.

To assist countries to introduce programmes to prevent and control cervical cancer, the World Health Organization developed the Cervical Cancer Prevention and Control Costing (C4P) tool [3] for the estimation of financial and economic costs over 5 years. The tool has two modules—one for estimating the incremental costs of introducing HPV vaccination (primary prevention) and the second for estimating the incremental costs of cervical cancer screening and treatment (secondary and tertiary prevention). An earlier paper [4] presented the assumptions and methods used for the first module. This paper will present the assumptions and methods used in the second module and the improvement in the first module. It will also present the overall estimated incremental costs of introducing vaccination and screening and treatment in Tanzania.

Tanzania had the fourth highest incidence rate of cervical cancer in the world in 2020 with 62.5 new cases per 100,000 women (age-standardized to the world population) [5]. Cervical cancer mortality is also high, with 42.7 deaths per 100,000 (age-standardized to the world population) in 2020 [5]. Tanzania’s high incidence of cervical cancer is linked to the burden of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in the country, with the HIV prevalence of female adults aged 15–49 at 6.0% in 2020 [6].

The Ministry of Health of Tanzania plans to reduce cervical cancer incidence and mortality [7] and reach elimination through scaling up prevention and control activities in the country. To inform domestic and external financial resource mobilization, the objective of this study is to estimate the financial and economic incremental cost of scaling up coverage of primary, secondary and tertiary cervical cancer prevention in Tanzania from 2020 to 2024. This study is a follow-up to the findings presented in an earlier 2012 publication [4] where the costs of introducing HPV vaccination in Tanzania were projected for the years 2011 to 2015. This study differs from the earlier one since it takes a comprehensive approach to prevent and control cervical cancer and includes projected costs of scaling up cervical cancer secondary and tertiary interventions in addition to vaccination as part of the global cervical cancer elimination strategy [2].

The Tanzanian cervical cancer prevention and control programme
The Tanzanian government has programmes to implement primary, secondary and tertiary prevention for cervical cancer as shown in Table 1. The country through the national Immunization and Vaccine Development Programme (IVD) introduced HPV vaccination on a pilot basis in 2014 and then scaled up nationally as part of the routine programme in 2018. The IVD provides two doses to girls aged 14 years through the routine programme annually with two service delivery strategies: (1) vaccination where girls visit health facilities to get the immunization and (2) vaccination by health workers who visit schools located near facilities to immunize all 14-year-old girls. It is assumed that the vaccine coverage in 2020 for 14-year-old girls would be 70% in 2020, and the coverage will increase to 85% by 2024.

The National Tanzanian Reproductive Health Programme is managing the cervical cancer secondary and tertiary prevention service provision. It oversees screening with visual inspection with acetic acid (VIA) services in 136 out of 169 districts at zonal, regional referral and district hospitals and some health centres and dispensaries. By 2019, the programme had screened 11% of its eligible women. The programme managers plan to gradually ramp up VIA screening capacity from 794 in 2020 to all of its 6447 facilities by 2024. They also plan to scale up HPV-DNA screening from all 30 regional referral hospitals beginning in 2020 to 88 facilities in 2024, including 58 district hospitals.
Women with a positive VIA or HPV screening test are treated with cryotherapy, if eligible, at the same visit in a single visit approach strategy (SVA) for small lesions and loop electrical excision procedures (LEEP) for larger lesions. Health providers offer cryotherapy at all regional referral hospitals, half of the district hospitals and health centres and some dispensaries (20%). LEEP is provided at all zonal and regional referral hospitals and a quarter of district hospitals.

Women who have lesions and are suspicious of cancer are referred for further evaluation and diagnosis with colposcopy and biopsies for histopathology assessment. If they are diagnosed with invasive cervical cancer, they are referred for treatment appropriate to the stage of the cancer, including radiotherapy, chemotherapy and/or palliative care. No surgery was available in the country for the treatment of invasive cancers. Treatment is provided at a few centres in the country—two regional referral hospitals for radiotherapy and 33 for chemotherapy. Outpatient palliative care is given at regional referral and district hospitals while inpatient palliative care is given at regional referral hospitals.

**Methods**

The C4P tool [3] is an Excel-based country-specific costing and planning tool that facilitates data collection and enables the user to estimate the value of incremental (additional) resources required to add the countrywide delivery of HPV vaccine to an existing immunization programme over a 5-year period and the resources required for scaling up cervical cancer screening and treatment services over a 5-year period. In other words, it only estimates the value of additional resources needed to introduce the vaccine or cervical cancer services and does not include the cost of the existing immunization or reproductive health programme or other goods and services (for example, transport) already being used for other vaccines (shared costs). The C4P tool separates costs into recurrent and capital as well as financial (monetary outlays) and economic (opportunity costs) ones. Recurrent costs are the value of resources that last less than 1 year, such as supplies and personnel time, while capital costs are the value of resources that last more than 1 year, such as equipment or vehicles (see Table 2). Startup costs are the value of resources used in the initial one-time programmatic activities such as initial training and planning and are treated as capital goods and depreciated if their useful life lasts more than a year.

Financial costs are the monetary outlays paid for HPV vaccination or cervical cancer services such as supplies and commodities. Economic costs comprise the value of all outlays for vaccine introduction or screening and treatment, regardless of the source of funding, and take into account donated goods. For economic costs, the value of resources purchased by agencies other than the National Tanzanian Reproductive Health Programme, such as health personnel time costs and donated vaccines, are included. This analysis does not include the value of existing capital goods used to deliver services such as equipment when these are assumed to have excess capacity.

The current HPV vaccination module of the C4P tool has been improved compared to the version used in the previous exercise [4]. Depending on the objectives of the costing exercise, it can be used to either project costs in a 5-year period or retrospectively estimate cost expenditure in a 5-year period. Also, the tool can not only cost single-age cohort vaccination, but also multiple-age cohort vaccination, which is applicable

---

### Table 1 Implementation strategies for cervical cancer prevention and control in Tanzania, 2020–2024

| Target population                              | Intervention                                      | Sites providing services                           |
|------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| **Vaccination**                                | Girls aged 14 years                               | 2 doses human papillomavirus vaccine [8]          |
|                                                |                                                   | Health centres, dispensaries, schools             |
| **Screening**                                  | Women living with human immunodeficiency virus: 15–49 years | Visual inspection with acetic acid HPV-DNA        |
|                                                | Women of the general population: 30–49 years      |                                                   |
|                                                |                                                   | Health centres, dispensaries, all hospitals*      |
|                                                |                                                   | Regional referral and district hospitals          |
| **Pre-cancer treatment**                       | Women with a positive screening test              | Cryotherapy                                       |
|                                                |                                                   | Loop electrical excision procedures              |
|                                                |                                                   | Health centres, dispensaries, regional referral and district hospitals |
| **Tertiary interventions for cancer**          | Screened women suspicious of cancer               | Diagnostics                                       |
|                                                |                                                   | Chemotherapy                                      |
|                                                |                                                   | Radiotherapy                                      |
|                                                |                                                   | Palliative care                                   |
|                                                |                                                   | All hospitals*                                    |
|                                                |                                                   | Regional referral hospitals                       |
|                                                |                                                   | Regional referral hospitals                       |
|                                                |                                                   | Health centres, regional referral and district hospitals |

* All hospitals include zonal, regional referral and district hospitals
Table 2 Activities for HPV vaccination and cervical cancer screening and treatment costed in the C4P tool

|                                 | HPV vaccination                  | Cervical cancer screening and treatment |
|---------------------------------|----------------------------------|----------------------------------------|
| **Startup costs**               | Microplanning                    | Programme planning/microplanning       |
|                                 | Training                          | Training                               |
|                                 | Sensitization/social mobilization | Sensitization/social mobilization/communication |
| **Recurrent**                   | Vaccine procurement               | Procurement of supplies                |
| Service delivery                | Personnel time                    | Personnel time                         |
| Programmatic                    | Per diems and travel allowances   | Laboratory tests                       |
|                                 | Monitoring and supervision        | Monitoring and supervision             |
| **Capital**                     | Cold chain                        | VIA and HPV-DNA equipment              |
|                                 | Other capital goods               | Cryotherapy machines                   |
|                                 |                                   | LEEP machine and other equipment       |
|                                 |                                   | Radiotherapy treatment                 |

DNA deoxyribonucleic acid, HPV human papillomavirus, LEEP loop electrosurgical excision procedure, VIA visual inspection with acetic acid

* Designated as capital costs if one-time cost and useful life is more than 1 year

...to countries that newly introduce HPV vaccine for the recommended age group and for catch-up in an older age group.

The C4P tool was used to compare the alternative strategies and ultimately to focus on the detailed costing of the strategic plan [3]. The costs of cervical cancer prevention and control interventions were projected for a 5-year period, 2020–2024. The HPV vaccination module (version 4.1) is used to project costs of vaccinating 14-year-old girls while the screening and treatment module (version 47.6.5) project the cost of providing cervical cancer services for two target populations: (1) women living with HIV that start screening at 15 years and (2) women from the general population that start screening at 30 years. Table 3 shows the activities that are costed in the two modules.

Costing screening and treatment services is more complicated than vaccination since it comprises seven services rather than one: two for screening, two for treating pre-cancer and three for diagnosis and treatment of invasive cancer. The cost per cervical cancer service includes health personnel time, supply and materials, capital goods and other costs. The assumptions and data sources made in the estimation of vaccination, screening and treatment costs for each service are shown in Table 3.

All costs are reported in 2019 US dollars (US$).

Data collection

The study team, comprising health economists, reproductive health specialists and epidemiologists, collected the data during two workshops in February and April 2019 in Dar Es Salaam with immunization and cervical cancer programme managers; the Ministry of Health, Community Development, Gender, Elderly and Children (MOHCDEC); and external partners (Joint United Nations Programme on HIV/AIDS, United States Center for Disease Control, Clinton Health Access Initiative, Johns Hopkins Program for International Education in Gynecology and Obstetrics, and London School of Hygiene and Tropical Medicine and WHO consultants). All participants attended the meetings in person. They collected information on time spent on service delivery using expert opinion, numbers of facilities/sites providing services, information on pricing and salaries and financial records on expenditures on planning, training, sensitization and monitoring as well as plans for scaling up service delivery.

Results

HPV vaccination costs

Table 4 shows the projected costs of the HPV vaccination during 2020–2024. The total annual financial costs, i.e. the monetary outlays by the government, range from US$3.2 million in 2020 to US$4.1 million in 2024, while the annual economic costs range from US$8.3 million to US$10.8 million. Economic costs are higher than financial ones since these include the value of donated vaccines and existing health personnel salaries. The financial and economic costs per fully immunized girl (FIGs) are projected to be US$6.68 and US$17.31, respectively.

The cost drivers for both financial and economic costs are vaccine and injection supply procurement (58.1% and 71.4%, respectively) and service delivery (33.4% and 24.0%, respectively) comprising personnel, per diem and transport (see Fig. 1 for a pie chart on financial cost distribution). Programmatic costs (including microplanning, training, sensitization, monitoring and supervision) account for about 8.4% of total financial costs and 4.5% of economic costs.

Cervical cancer secondary and tertiary prevention programme costs

Table 5 shows the estimated unit cost per screening and treatment service based on the assumptions of the
### Table 3: Inputs used in cervical cancer prevention and control services

| Variable name                        | Assumption                                                                 | Source                                      | Variable name                        | Assumption                                                                 | Source                                      |
|--------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------|--------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------|
| **Vaccination**                      |                                                                             |                                             | **Screening and treatment**           |                                                                             |                                             |
| Target population                    | 14-year-old girls; 670,905                                                  | National Bureau of Statistics               | Target population                    |                                                                             | World Population Prospects 2019            |
| Vaccination site                     | Health facility: 40% At school: 55% Mobile outreach: 5%                     | Programme managers                          | % women assumed to be living with HIV |                                                                             |                                             |
| Coverage (second dose of 2-dose vaccine) | 2020: 70% 2021: 72% 2022: 79% 2023: 80% 2024: 85%                          | Workshop expert opinion                     | Screening coverage                   | 2020: 15% 2021: 20% 2022: 25% 2023: 30% 2024: 35%                          | Workshop expert opinion                     |
| Training                             | Council cascade and annual refreshers                                      | Expert opinion                              | Epidemiology evaluation/quality assurance of the programme | HPV— 90.2% HPV+/none: 1.6% Small lesions: 4.8% Large lesions: 0.4% Invasive cancer: 3.0% | Programme managers                          |
| Cold chain                           | No additional cold chain required                                           | Programme managers                          | Rescreening # of years                | HIV+: 30 years HIV−: 50 years                                               | Programme managers                          |
| Health staff time                    | 5 min nurse or medical attendant per vaccination                           | Workshop expert opinion                     | Health staff time                    | HPV-DNA test 15 min (RN)                                                   | Workshop expert opinion                     |
|                                     |                                                                             |                                             | Cytology                             | 20 min each (RN, EN)                                                        |                                             |
|                                     |                                                                             |                                             | Cryotherapy                          | 20 min each (RN, EN)                                                        |                                             |
|                                     |                                                                             |                                             | LEEP                                 | 35 min (specialist, MO, AMO)                                                |                                             |
|                                     |                                                                             |                                             | CSDR                                 | 40 min each (oncologist, EN)                                                |                                             |
|                                     |                                                                             |                                             | Chemotherapy                         | 720 min oncologist, 2520 min (RN, EN)                                       |                                             |
|                                     |                                                                             |                                             | Radiotherapy                         | 135 min MO, 180 min (RN, PH), 280 min RO, 500 min RT                       |                                             |
|                                     |                                                                             |                                             | Palliative out/in                    | 15 min AMO                                                                  |                                             |
| Local school visit transport         | Per diem allowance of US$13 (30,000 TZA) and transport allowance            | Programme managers                          | Existing equipment with excess capacity (not costed) | Waiting area, examination area, gynaecological examination couch          | Workshop interviews                          |
| Vaccine price per dose               | US$4.50 per dose                                                            | Gavi                                        | Laboratory test prices               | Not applicable                                                               | NHIF price schedule                        |
| Donations                            | 80% of vaccine, injection supplies and shipping donated by Gavi             | Gavi                                        | Equipment prices                    | Not applicable                                                               | MDA, UNFPA, UNICEF, WHO                    |
| Assumptions relevant to both prevention and control services |                                                                             |                                             |                                      |                                                                             |                                             |
| Exchange rate                        | 2304 TZA to US$1                                                            | Oanda                                       | Discount rate                       | 7.0% (Bank of Tanzania)                                                     | Central bank rate                           |

AMO assistant medical officer, CSDR comprehensive screening, diagnostic and referral, DNA deoxyribonucleic acid, EN enrolled nurse, HIV human immunodeficiency virus, HPV human papillomavirus, LEEP loop electrosurgical excision procedure, MDA Medical Device Authority, MO medical officer, NHIF National Health Insurance Fund, PH physicist, RN registered nurse, RT radiotherapy technician, UNFPA United Nations Population Fund, VIA visual inspection with acetic acid, WHO World Health Organization.
prices and quantities of resources needed. The service with the lowest cost is VIA screening, and the costliest one is radiotherapy cancer therapy.

Table 6 presents the projected costs of cervical cancer secondary and tertiary prevention programme costs during 2020–2024. The total cost of the programme over 5 years is projected to be US$49.9 million and US$78.20 million for financial and economic costs, respectively. Most of the projected costs are for service delivery (82% for financial costs and 72% for economic costs). The remaining projected financial and economic costs (18% and 28%, respectively) are for programmatic costs, i.e. monitoring and supervision, programme planning/microplanning, training and sensitization/social mobilization.

Among all services, the largest share of projected costs is for screening, followed by diagnosis and cervical cancer treatment. The largest share of programmatic costs is for sensitization/social mobilization.

Table 4 Costing summary of HPV vaccination in 2020–2024 (2019 US dollars)

| Coverage | 2020  | 2021  | 2022  | 2023  | 2024  | Total  | Percentage |
|----------|-------|-------|-------|-------|-------|--------|------------|
| First dose | 80%   | 82%   | 85%   | 87%   | 90%   | 85%    | NA         |
| Second dose | 70%   | 72%   | 75%   | 80%   | 85%   | 77%    |            |
| Drop-out | 12.5%  | 12.2%  | 11.8%  | 8%    | 5.6%  | 12.5%  |            |

Financial

| Startup (US$000s) (annualized) | 2020  | 2021  | 2022  | 2023  | 2024  | Total  | Percentage |
|--------------------------------|-------|-------|-------|-------|-------|--------|------------|
| Microplanning | 25    | 25    | 25    | 25    | 25    | 125    | 0.7       |
| Training | 78    | 78    | 78    | 78    | 78    | 386    | 2.1       |
| Sensitization | 78    | 78    | 78    | 78    | 78    | 390    | 2.1       |

Recurrent (US$000s)

| Vaccine procurement | 1853  | 1962  | 2101  | 2261  | 2443  | 10,621 | 58.1      |
| Service delivery | 1066  | 1128  | 1208  | 1302  | 1405  | 6108   | 33.4      |
| Monitoring and supervision | 129   | 129   | 129   | 129   | 129   | 644    | 3.5       |

Total financial costs (US$000s) | 3229  | 3400  | 3619  | 3874  | 4158  | 18275  | 100%      |

Economic

| Startup (US$000s) (annualized) | 2020  | 2021  | 2022  | 2023  | 2024  | Total  | Percentage |
|--------------------------------|-------|-------|-------|-------|-------|--------|------------|
| Microplanning | 30    | 30    | 30    | 30    | 30    | 138    | 0.3       |
| Training | 105   | 105   | 105   | 105   | 105   | 481    | 1.0       |
| Sensitization | 94    | 94    | 94    | 94    | 94    | 429    | 0.9       |

Recurrent (US$000s)

| Vaccine procurement | 5899  | 6244  | 6688  | 7200  | 7775  | 33,806 | 71.4      |
| Service delivery | 1984  | 2100  | 2250  | 2422  | 2615  | 11,370 | 24.0      |
| Monitoring and supervision | 220   | 220   | 220   | 220   | 220   | 1102   | 2.3       |

Total economic costs (US$000s) | 8332  | 8793  | 9387  | 10,071| 10,839| 47,327 | 100%      |

Number of FIGs | 469,634| 497,998| 534,646| 588,497| 644,036| 2,734,810| 100% |

Financial cost per FIG with vaccine costs | NA | NA | NA | NA | NA | $6.68 | NA |

Economic cost per FIG with vaccine costs | NA | NA | NA | NA | NA | $17.31 | NA |

FIG fully immunized girls; costs reported in 2019 US dollars (US$)

a Refers to 20% vaccine purchase and freight, handling and insurance charges

b Due to substantial one-time costs necessarily being spread over the 5 years and personnel costs being calculated per vaccination, the per FIG annual costs would not adequately reflect service volume. See instead the aggregate costs divided by the total numbers of fully immunized girls for the 5 years in the “Total” column.
Discussion
The C4P tool allows programme managers working in low- and middle-income countries such as Tanzania to work with a study team and stakeholders to co-create a projection of the incremental costs of scaling up their programmes, for primary, secondary and tertiary prevention. The tool is a central part of a process that allows programme managers to consider the financial implications of alternative approaches to scaling up a cervical cancer programme. Furthermore, it acts as a

Table 5  Cervical cancer services’ projected numbers provided and costs in 2020–2024 (2019 US dollars)

| Screening and treatment service | Projected number of services provided in 5 years | Financial cost per service | Economic cost per service |
|--------------------------------|---------------------------------------------------|---------------------------|--------------------------|
| **Screening**                  |                                                   |                           |                          |
| VIA                            | 4,750,216                                         | $3.66                     | $5.54                    |
| HPV-DNA testing                | 327,364                                           | $9.20                     | $10.03                   |
| **Pre-cancer**                 |                                                   |                           |                          |
| Cryotherapy                     | 117,549                                           | $5.14                     | $7.21                    |
| LEEP                           | 9796                                              | $56.79                    | $70.03                   |
| **Cancer**                     |                                                   |                           |                          |
| Diagnosis                       | 73,615                                            | $100.65                   | $106.60                  |
| Chemotherapy                    | 18,395                                            | $292.56                   | $574.52                  |
| Radiotherapy                    | 7361                                              | $800.21                   | $893.80                  |
| Palliative care (outpatient)    | 9325                                              | $7.05                     | $7.83                    |
| Palliative care (inpatient)     | 491                                               | $33.57                    | $34.36                   |

DNA deoxyribonucleic acid, HPV human papillomavirus, LEEP loop electrosurgical excision procedure, VIA visual inspection with acetic acid

Fig. 1  Composition of financial costs of HPV vaccine delivery in 2020–2024
a catalyst for key stakeholders to engage in substantive discussions about how they can coordinate their efforts to avoid bottlenecks and gaps in the service delivery workflow. As the process of completing the tool progresses, programme managers, policymakers, donors and funders ideally will reach a convergence in their

Table 6  Costing summary of cervical cancer secondary and tertiary prevention in 2020–2024 (2019 US dollars)

| Coverage assumptions          | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|------------------------------|------|------|------|------|------|-------|------------|
| Screening                    | 15%  | 20%  | 25%  | 30%  | 35%  | N/A   | N/A        |
| Drop-out for treatment if HPV+| 50%  | 50%  | 50%  | 50%  | 50%  | N/A   | N/A        |

**Financial costs (000s)**

| Service delivery              | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|------------------------------|------|------|------|------|------|-------|------------|
| Screening                    | 2712 | 3467 | 4119 | 4783 | 5333 | 20,413| 40.9%      |
| Pre-cancer                   | 208  | 230  | 243  | 233  | 246  | 1161  | 2.3%       |
| Diagnosis and cancer         | 3320 | 3816 | 4026 | 3865 | 4077 | 19,105| 38.3%      |

| Programmatic support         | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|------------------------------|------|------|------|------|------|-------|------------|
| Microplanning                | 62   | 62   | 62   | 62   | 62   | 310   | 0.6%       |
| Training                     | 64   | 64   | 64   | 64   | 64   | 320   | 0.6%       |
| Sensitization/social mobilization | 1505 | 1505 | 1505 | 1505 | 1505 | 7526  | 15.1%      |
| Monitoring and supervision   | 204  | 204  | 204  | 204  | 204  | 1020  | 2.0%       |
| Total financial costs        | 8075 | 9348 | 10,223 | 10,717 | 11,491 | 49,853 | 100%      |

**Economic costs (000s)**

| Service delivery              | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|------------------------------|------|------|------|------|------|-------|------------|
| Screening                    | 4130 | 5120 | 6041 | 6779 | 7550 | 29,620| 37.9%      |
| Pre-cancer                   | 276  | 305  | 321  | 308  | 324  | 1534  | 2.0%       |
| Diagnosis and cancer         | 4458 | 5102 | 5328 | 5155 | 5394 | 25,427| 32.5%      |

| Programmatic support         | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|------------------------------|------|------|------|------|------|-------|------------|
| Microplanning                | 151  | 151  | 151  | 151  | 151  | 755   | 1.0%       |
| Training                     | 92   | 92   | 92   | 92   | 92   | 460   | 0.6%       |
| Sensitization/social mobilization | 3748 | 3748 | 3748 | 3748 | 3748 | 18,741| 24.0%      |
| Monitoring and supervision   | 330  | 330  | 330  | 330  | 330  | 1651  | 2.1%       |
| Total economic costs         | 13,185 | 14,848 | 16,011 | 16,562 | 17,579 | 78,423 | 100%      |

* Drop-out rate assumes high loss to follow-up for the treatment of pre-cancer due partly to logistical difficulties for cryotherapy and LEEP and for invasive cancer due to the limited availability of tertiary health centres

Table 7  Total projected costs of cervical cancer prevention and control in 2020–2024 (2019 million US dollars)

| Programme areas                          | 2020  | 2021  | 2022  | 2023  | 2024  | Total  | Percentage |
|------------------------------------------|-------|-------|-------|-------|-------|--------|------------|
| Financial                                 |       |       |       |       |       |        |            |
| Costs of HPV vaccination (including programmatic costs) | 3.2   | 3.4   | 3.6   | 3.9   | 4.2   | 18.3   | 27.1%      |
| Service delivery costs of screening and pre-cancer treatment | 2.9   | 3.6   | 4.3   | 4.9   | 5.5   | 21.2   | 31.4%      |
| Service delivery costs of cancer diagnosis, treatment and palliative care | 3.3   | 3.8   | 4.0   | 3.9   | 4.1   | 19.1   | 28.3%      |
| Programmatic costs of secondary and tertiary prevention | 1.8   | 1.8   | 1.8   | 1.8   | 1.8   | 9.2    | 13.3%      |
| Total                                    | 11.2  | 12.6  | 13.7  | 14.5  | 15.6  | 67.6   | 100.0%     |
| Economic                                 |       |       |       |       |       |        |            |
| Costs of HPV vaccination (including programmatic costs) | 8.3   | 8.8   | 9.4   | 10.0  | 10.8  | 47.3   | 38.3%      |
| Service delivery costs of screening and pre-cancer treatment | 4.3   | 5.4   | 6.3   | 7.0   | 7.8   | 30.8   | 24.9%      |
| Service delivery costs of cancer diagnosis, treatment and palliative care | 4.5   | 5.1   | 5.3   | 5.2   | 5.4   | 25.5   | 20.6%      |
| Programmatic costs of secondary and tertiary prevention | 4.0   | 4.0   | 4.0   | 4.0   | 4.0   | 20.0   | 16.2%      |
| Total                                    | 21.1  | 23.3  | 25.0  | 26.6  | 28.0  | 123.6  | 100.0%     |
understanding of what needs to be done and how much it will cost to do it. This, in turn, aids champions of a cervical cancer programme to plan and advocate for resources for their programme so that they can reach their goals of reductions in mortality and morbidity and eventually elimination.

The process to estimate the costs of scaling up a comprehensive cervical cancer programme involves setting up a team of health economists, epidemiologists, clinicians and programme managers from both the immunization and the cancer units or programmes. Using the C4P tool effectively requires a trained health economist to be part of the study team and therefore involves training local health economists to use the tool. An additional benefit of the process is that the health system is strengthened since the capacity of local health economists in costing health programmes is improved.

The results of the pilot in Tanzania indicate that the cost driver for vaccination is vaccine procurement (58% and 71% of financial and economic costs, respectively). For non-vaccine costs, the cost driver is service delivery (33% and 24%, respectively), i.e. personnel salaries (for economic costs), transport and per diem. Programmatic activities (i.e. microplanning, training, sensitization and monitoring and evaluation) comprise a smaller proportion (8% of financial costs and 5% of economic costs) since these improve service demand and quality. The costliest programmatic activity is monitoring and supervision.

When the projected costs of vaccination are compared to the 2012 study by Hutubessy et al. in Tanzania [4], these decreased by 37% due to a change in the number of doses of HPV vaccines and a lower percentage of vaccinations taking place at schools. That is, the WHO recommended number of vaccine doses per girl has declined from three to two [8], leading to lower projected costs for procurement. In addition, in the 2012 study, it was assumed that all vaccines would be given at schools while this study assumes that approximately half of the target population would be vaccinated in health facilities and the other half in schools, leading to lower service delivery costs. Other projected costs have increased in this study, e.g. the cost per service delivery visit has increased due to higher per diems and travel allowances.

The projected financial annual costs of cervical cancer screening and treatment range from $8.0 million in 2020 to $11.4 million in 2024 while projected economic annual costs range from $13.1 million in 2020 to $17.5 million in 2024. The service with the highest share of costs is screening (combination of VIA and HPV-DNA testing) since the projected service volume is significantly higher than that for pre-cancer and cancer services even though the latter costs per service are much higher. Programmatic costs also comprise a large share, i.e. 16.3% and 25.6% for financial and economic costs, respectively.

To understand the context of implementing cervical cancer prevention and control in Tanzania, the proportion of the annual health budget that would be required to finance the programme was calculated. The estimated proportion of the annual 2020/2021 health budget of Tanzania [10] that would be required is 1.4%, and this suggests that a comprehensive prevention and control programme is likely to be affordable.

The costs of screening and treatment are similar to those found in other studies in low- and lower-middle-income countries. The cost of a woman screened with VIA in other studies US$3.33 [11] to US$3.67 [12] compares well with US$3.66 to US$5.44 in this study. The cost of a woman screened with HPV-DNA testing in other studies [US$6.27 to US$15.92] [13] is in the range of this study’s estimates [US$9.20 to US$10.03]. The estimate of a cryotherapy service in this study, US$5.14 to US$7.21, is lower, however, than in other studies, e.g. US$38 [11] or US$28.97 [12], possibly because the costs of equipment were calculated differently, i.e. these were divided by total national expected cases rather than by the number of cases referred to tertiary or referral hospitals. The costs of cancer services in this study, though, are similar to those found in Nelson et al. [14].

This study has some limitations. The first limitation of our study is that we illustrated the application of the C4P tool based only on the Tanzania Strategic Plan Cervical Cancer Prevention and Control [7], which had been developed before new WHO guidelines for cervical cancer prevention and control had been published. The C4P tool has the capability of comparing scenarios and could potentially have been used to calculate the costs of relevant alternative strategies such as 1-dose HPV vaccine regimes, self-collected samples for HPV testing and thermal ablation. The second limitation relates to the short 5-year study period of the C4P tool, which reflects its emphasis on programme management rather than policymaking. The impact of vaccination is realized only in the longer term, and so the significant cost savings of reductions in treatment for pre-cancer and for downstaged invasive cancer are not captured by the tool. The third limitation is that data collection did not include the sampling of health facilities due to the limited time frame and budget for the study. A final limitation of the C4P tool is that a formal uncertainty or sensitivity analysis is not included in the tool itself.

If Tanzania can scale up these services for the prevention and control of cervical cancer, there will be an important impact on cervical cancer morbidity and mortality over the medium and long term. The impact, though, will be affected by whether there is compliance...
with referrals and accurate diagnoses and effective treatment. So, it will be important during the scale-up not only to focus just on increasing the number of sites that provide services but also to ensure the quality of services. It will also be important to ensure the equity of service provision and access to screening and pre-cancer services at lower levels of the health system.

Conclusions

The C4P tool modules for vaccination and screening and treatment can assist national cervical cancer programmes to estimate monetary resources needed as well as opportunity costs of reducing national cervical cancer incidence through primary, secondary and tertiary prevention.

Abbreviations

AIDS: Acquired immunodeficiency syndrome; AMO: Assistant medical officer; C4P: Cervical Cancer Prevention and Control Costing; CSDR: Comprehensive screening, diagnostic and referral; DNA: Deoxyribonucleic acid; EN: Enrolled nurse; FIG: Fully immunized girl; HPV: Human immunodeficiency virus; HPV: Human papillomavirus; IVD: Immunization and Vaccine Development Programme; LEEP: Loop electrosurgical excision procedure; MDA: Medical Device Authority; MO: Medical officer; MOH/DEC: Ministry of Health, Community Development, Gender, Elderly and Children; NHIF: National Health Insurance Fund; PH: Physicist; RN: Registered nurse; RT: Radiotherapist technician; SVA: Single visit approach strategy; UNFPA: United Nations Population Fund; UNJGP: United Nations Joint Global Programme; VIA: Visual inspection with acetic acid; WHO: World Health Organization.

Acknowledgements

We thank the participants of the WHO workshops on the cervical cancer programme costing for Tanzania in Dar es Salaam, United Republic of Tanzania, in February and April 2019. The views expressed are those of the authors and do not necessarily represent the views of the World Health Organization.

Authors’ contributions

AL, RH and KY contributed to the conception and design of the study and the C4P tool. AL and WM developed the C4P tool under supervision and directions from RH, KY and NB. RH, SY, AL and ES were responsible for the acquisition of the data in Tanzania. AL and WM analyse and interpreted the data. All co-authors have been involved in drafting the manuscript or revising it critically for important intellectual content. The authors read and approved the final manuscript.

Funding

The costing exercise in Tanzania was part of the United Nations Joint Global Programme (UNJGP) on Cervical Cancer Prevention and Control funded by WHO. The Gavi Alliance and the Bill and Melinda Gates Foundation funded the development of the earlier version of the WHO C4P tool.

Availability of data and materials

The C4P tool is publicly available at https://www.who.int/tools/who-cervical-cancer-prevention-and-control-costing-(c4p)-tool. The Tanzanian costing data is available upon request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Levin & Morgan LLC, Bethesda, USA. 2. Ministry of Health, Dodoma, United Republic of Tanzania. 3. World Health Organization, Dar es Salaam, United Republic of Tanzania. 4. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada. 5. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. 6. Department of Immunisation, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Received: 11 March 2022 Accepted: 22 September 2022 Published online: 01 November 2022

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.
2. World Health Organization, Global strategy towards eliminating cervical cancer as a public health problem. Geneva: World Health Organization; 2020 (https://www.who.int/initiatives/cervical-cancer/strategy).
3. World Health Organization, WHO Cervical Cancer Prevention and Control Costing (C4P) tool. https://www.who.int/tools/who-cervical-cancer-prevention-and-control-costing-(c4p)-tool.
4. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing tool. BMC Med. 2012;10:136.
5. IARC/WHO Tanzania human papillomavirus and related cancers, fact sheet 2021. IICO/IARC HPV Information Centre. Barcelona, Spain. (http://www.hpvcentre.net).
6. United Republic of Tanzania Fact Sheet 2022 [website]. Geneva: UNAIDS, 2022 (https://www.unaids.org/en/regionscountries/countries/unitedrepublicoftanzania).
7. United Republic of Tanzania, Tanzania Strategic Plan Cervical Cancer Prevention and Control (2020-2024). Ministry of Health, Community Development, Gender, Elderly & Children, Dodoma, Tanzania, 2019.
8. World Health Organization, SAGE Working Group on potential contribution of human papillomavirus vaccines and immunization towards cervical cancer elimination, 2017.
9. Tanzania HIV Impact Survey (A population-based HIV impact assessment) 2016-2017; Final Report. https://www.malecircumcision.org/resource/tanzania-hiv-impact-survey-2016-%28%2902/2017-final-report. Accessed 13 November 2019.
10. United Republic of Tanzania, Ministry of Financing and Planning. The citizens budget: a simplified version of the government budget for the financial year 2020/2021. https://www.mof.go.tz/docs/news/CITIZEN%20BUDGET%20ENGLISH%20VERSION%202020%2021.pdf.
11. Mvundura M, Tsvi V. Estimating costs of cervical cancer screening in high-burden Sub-Saharan African countries. Gynecol Obstet. 2014. https://doi.org/10.1016/j.jgo.2014.02.012.
12. Linch-DeRoche N, Phiri J, Michelow P, Smith J, Finhaber C. Costs and cost-effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa. PLoS One 2015;10(11):e0141969. https://doi.org/10.1371/journal.pone.0141969.
13. Campos N, Sharma M, Clark A, Lee K, Geng F, Regan C, et al. The health and economic impact of scaling cervical cancer prevention in 50 low and lower-middle-income countries. Int J Gynecol Obstet. 2017;138(Suppl.1):47–56.
14. Nelson S, Kim J, Wilson F, Soliman A, Ngoma T, Kakhasa C, et al. Cost-effectiveness of screening and treatment for cervical cancer in Tanzania: implications for other Sub-Saharan African countries. Value Health Reg Issues. 2016;10:1–6. https://doi.org/10.1016/j.vhri.2016.03.002.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.